@article{75cfa57943164b908a37a2ab3f14128a,
title = "Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan",
abstract = "Background: While direct-acting antivirals have been approved for treating hepatitis C, the guidelines highlight the importance of considering potential drug-drug interactions between DAAs and concomitant medications. Aim: To assess comorbidity prevalence, concomitant medication use and potential drug-drug interactions between DAAs and concomitant medications for hepatitis C patients in Taiwan. Methods: This cross-sectional study enrolled 822 patients from May to August 2016 in Taiwan. Patient demographics, comorbidities and concomitant medications were evaluated by physician surveys. Results: A total of 709 (86.3\%) patients had ≥1 comorbidity; the most prevalent comorbidity categories were diseases of the digestive system (40.1\%), circulatory system (38.7\%) and endocrine/nutritional/metabolic diseases (35.2\%). Elderly patients had more comorbidities. A total of 622 (75.7\%) patients received ≥1 concomitant medication; the average number of concomitant medications was 3.2. The most common concomitant medication classes were cardiovascular (34.4\%), gastrointestinal (25.7\%) and central nervous system drugs (22.7\%). Among patients without cirrhosis or with compensated cirrhosis, contraindications were most prevalent with paritaprevir/ritonavir/ombitasvir plus dasabuvir, daclatasvir/asunaprevir and glecaprevir/pibrentasvir (13.3\%, 6.0\% and 5.4\% respectively), and least prevalent with sofosbuvir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir and sofosbuvir/velpatasvir (0.8\%, 1.3\%, 1.4\% and 2.1\% respectively). Sofosbuvir-based regimens had no contraindications in patients with decompensated cirrhosis. Conclusion: Our population represented an elderly demographic, with a high prevalence of comorbidities and widespread use of concomitant medications. The potential drug-drug interactions between these concomitant medications and DAA regimens differed, with the fewest potential interactions with sofosbuvir-based regimens.",
author = "Liu, \{Chen Hua\} and Yu, \{Ming Lung\} and Peng, \{Cheng Yuan\} and Hsieh, \{Tsai Yuan\} and Huang, \{Yi Hsiang\} and Su, \{Wei Wen\} and Cheng, \{Pin Nan\} and Lin, \{Chih Lin\} and Lo, \{Ching Chu\} and Chen, \{Chi Yi\} and Chen, \{Jyh Jou\} and Qian Ma and Craig Brooks-Rooney and Kao, \{Jia Horng\}",
note = "Funding Information: This study was funded by Gilead Sciences. All costs associated with the development of this manuscript were funded by Gilead Sciences. The authors acknowledge Jing Kai Soh, Julian Ang, Ma Chang and Carol Kao from Costello Medical for data entry and analysis support, and Bryony Langford and Megan Besford from Costello Medical for DDI analysis support. Further acknowledgments are extended to Linical Co. Ltd for centre co‐ordination. Funding Information: Funding information This study was funded by Gilead Sciences. All costs associated with the development of this manuscript were funded by Gilead Sciences. The authors acknowledge Jing Kai Soh, Julian Ang, Ma Chang and Carol Kao from Costello Medical for data entry and analysis support, and Bryony Langford and Megan Besford from Costello Medical for DDI analysis support. Further acknowledgments are extended to Linical Co. Ltd for centre co-ordination. The authors acknowledge Jing Kai Soh, Julian Ang, Ma Chang and Carol Kao from Costello Medical for data entry and analysis support, and Bryony Langford and Megan Besford from Costello Medical for DDI analysis support. Further acknowledgments are extended to Linical Co. Ltd for centre coordination. Declaration of personal interests: Chen-Hua Liu has served as a speaker, a consultant and an advisory board member for Gilead Sciences, AbbVie and Merck Sharp \& Dohme, and has received research funding from AbbVie and Merck Sharp \& Dohme. Ming-Lung Yu has served as a speaker for AbbVie, Ascletis, Bristol-Myers Squibb, Gilead Sciences, Merck and PharmaEssentia, a consultant for AbbVie, Ascletis, Bristol-Myers Squibb, Gilead Sciences, Merck, Novartis and PharmaEssentia, and has received research funding from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck. Cheng-Yuan Peng has served as an advisory board member for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck Sharp \& Dohme. Wei-Wen Su has served as a speaker for AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck, and a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and PharmaEssentia. Pin-Nan Cheng has served as a speaker, a consultant and an advisory board member for Gilead Sciences, Bristol-Myers Squibb, and Merck Sharp \& Dohme, and has received research funding from Gilead Sciences. Qian Ma and Craig Brooks-Rooney are employees of Costello Medical, which was funded by Gilead Sciences to provide research, writing and editorial services for this manuscript. Tsai-Yuan Hsieh, Yi-Hsiang Huang, Chih-Lin Lin, Ching-Chu Lo, Chi-Yi Chen, Jyh-Jou Chen and Jia-Horng Kao have no interests to declare. Publisher Copyright: {\textcopyright} 2018 John Wiley \& Sons Ltd",
year = "2018",
month = dec,
doi = "10.1111/apt.15011",
language = "English",
volume = "48",
pages = "1290--1300",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "John Wiley and Sons Inc.",
number = "11-12",
}